Teva Pharmaceutical Industries Limited (TLV:TEVA)
Market Cap | 71.37B |
Revenue (ttm) | 61.87B |
Net Income (ttm) | -4.79B |
Shares Out | n/a |
EPS (ttm) | -4.25 |
PE Ratio | n/a |
Forward PE | 6.87 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,224,564 |
Average Volume | 1,920,120 |
Open | 6,284.00 |
Previous Close | 6,264.00 |
Day's Range | 6,226.00 - 6,373.00 |
52-Week Range | 4,865.00 - 8,431.00 |
Beta | 0.61 |
RSI | 57.05 |
Earnings Date | Jul 30, 2025 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space
Chaco vs. Teva — we tested the 2 most popular hiking sandals to see how they compare
We compared the Teva Hurricane XLT 2 and the Chaco Z/1 Classic sandals on features like their strap system, footbed, arch design, and color selection.

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech (NASDAQ: ALVO) on Thursday collaborated with Dr. Reddy's Laboratories Ltd. (NYSE: RDY) to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for gl...
How Do Investors Really Feel About Teva Pharmaceutical Indus?
Teva Pharmaceutical Indus's (NYSE: TEVA) short percent of float has risen 36.14% since its last report. The company recently reported that it has 38.70 million shares sold short , which is 3.39% of a...
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript
Teva Pharmaceutical prices and manages debt

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announ...

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announ...

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results fro...
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation ...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the present...

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd . (NYSE: TEVA) hosted 2025 Innovation & Strategy Day on Thursday to launch the acceleration phase of its “Pivot to Grow...

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acce...
Teva wins new Buy at Truist ahead of Innovation & Strategy Day

Here are Wednesday's biggest analyst calls: Nvidia, Apple, Broadcom, Microsoft, Teva, AutoZone, Vail & more
Here are Wednesday's biggest calls on Wall Street.

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celi...

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming ...

Why Is Teva Stock Trading Higher On Tuesday?
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymp...

Why Is Teva Stock Trading Higher On Tuesday?
Teva Pharmaceutical Industries Ltd TEVA and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin...

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
REHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”), a biotechnology c...
Why Investors Should Watch Teva Despite Regional Risks

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender offe...
Teva announces upsizing and pricing of $2.3B senior notes

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately...

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB...